Intracellular alpha-fetoprotein mitigates hepatocyte apoptosis and necroptosis by inhibiting endoplasmic reticulum stress

Chen YF, Liu SY, Cheng QJ, Wang YJ, Chen S, Zhou YY, Liu X, Jiang ZG, Zhong WW, He YH

Abstract

Key Words: Alpha-fetoprotein; Endoplasmic reticulum stress; Necroptosis; Apoptosis; Liver injury

lNTRODUCTlON

Chronic liver diseases, such as chronic hepatitis B (CHB), affect many patients, especially in East Asia,such as China. However, the pathogenesis of chronic liver diseases remains unclear. Although human liver has powerful capacity to compensate the disease-related liver injury, how hepatocytes respond and defense against these diseases has not been clarified. Hence, it is of great significance to clarify it for the management of patients with chronic liver diseases.

Alpha-fetoprotein (AFP) is a protein with similar biological function to albumin and secreted mainly by embryonic tissue cells physiologically and malignant hepatocytes pathologically after birth. Elevated levels of serum AFP have been considered as a reliable biomarker for prediction of birth defect and diagnosis of liver cancer, teratoma, renal cell carcinoma, and pancreatic cancer[1] although moderate serum AFP levels can be temporarily detected in individuals with aberrant liver regeneration, hepatitis,and chronic liver disease. Furthermore, low levels of serum AFP have been continually observed in patients with liver cirrhosis and positively correlated with the degrees of liver inflammation and fibrosis[2,3]. The low and moderate levels of serum AFP are likely from the activation and proliferation of liver precursor cells, including oval cells, hepatic progenitor cells, in response to severe liver damages, particularly in liver failure[4-6]. While hepatocyte proliferation usually compensates for mild and moderate liver injury, liver precursor cells can differentiate into hepatocytes and bile duct cells, promoting liver regeneration. The activated liver precursor cells can secrete AFP and high levels of serum AFP have been suggested to be a biomarker of better prognosis of liver failure[7,8]. However, it is unclear whether chronic liver injury can induce AFP expression and secretion in differentiated mature hepatocytes, and how the induced AFP modulates the pathogenic process of chronic liver diseases.

It is notable that endoplasmic reticulum (ER) stress contributes to the pathogenesis of chronic liver diseases[9,10] and is regulated by inositol requiring enzyme-1 and activating transcription factor-6(ATF6) and protein kinase R-like ER kinase (PERK)/eukaryotic translational initiation factor 2 alpha(eIF2α) signaling[11,12]. Aberrant ER stress can activate cell injury reactions, such as apoptosis and necroptosis by activating the C/enhancer binding protein (EBP)-homologous protein (CHOP) pathway,caspase-3 cleavage and mixed lineage kinase domain-like pseudokinase (MLKL) phosphorylation[13,14]. Our previous study has shown that ER stress inhibits the AFP secretion in hepatoma cells and the increase in the levels of intracellular AFP feedback attenuates the ER stress-related apoptosis and necroptosis in hepatoma cells[15]. However, it is unknown how ER stress can regulate AFP expression and secretion, and how intracellular AFP can modulate the ER stress-induced liver injury during the pathogenic process of chronic liver diseases.

In this research, we focus on whether intracellular AFP exists in hepatocytes during the liver injury,its regulatory relationship with ER stress, and its role in hepatocyte injury through clinical research,in vivoandin vitroexperiments.

MATERlALS AND METHODS

Clinical samples

A total of 34 biopsied liver specimens were collected from CHB patients, eight surgical liver specimens were obtained from patients with hepatic trauma, and another eight surgical liver specimens were obtained from patients with hepatocellular carcinoma (HCC) in the Department of Infectious Diseases,or Hepatobiliary Surgery, the Affiliated Hospital of Zunyi Medical University since 2012. The patients with CHB were diagnosed, according to the Guidelines for Prevention and Treatment of Chronic Hepatitis B revised in 2019[16]. Individual patients were excluded if she/he had current infectious disease, autoimmune liver disease, liver malignant tumor, alcoholic liver disease, drug-induced liver disease, multiple organ dysfunction syndrome, obvious bleeding tendency, deep jaundice, obvious ascites, or another situation not suitable for liver biopsy. Their demographic and clinical data are shown in Table 1. The experimental protocol was approved by the Ethics Committee of Affiliated Hospital of Zunyi Medical University (ZYFYLS[2018]28).

Establishment of liver injury in mice

Male BALB/c mice (25.0 g ± 3.0 g) were purchased from the Animal Center of Zunyi Medical University(Guizhou Province, China; SYXK[Qin] 2021-0004). The mice were maintained in a specific pathogen-free facility with a controlled temperature (20 °C-24 °C), a 12-h light/dark cycle and allowed free access to food and waterad libitum. The experimental protocol was established, according to the Animal Care and Research guidelines[17] and approved by the Animal Experiment Ethics Committee of Zunyi Medical University (LS[2020]2-231).

To induce liver injury by carbon tetrachloride (CCl4) administration, the mice were randomized using a random number table into the healthy control group (NC; untreated), solvent control group (olive oil,5 mL/kg, intraperitoneally,i.p.) and CCl4group (1 mL/kg mixed with 4 mL of olive oil,i.p.) (n= 12 per group). The mice in the solvent and CCl4group were administrated with solvent or CCl4once or twice per week for 8 wk. Their peripheral blood samples were collected 24 h after the last dose, euthanized and their liver tissues were dissected.

To induce ER stress-related liver injury, the mice were randomized into the healthy NC (untreated),solvent control (phosphate buffer saline, PBS, 10 mL/kg) and tunicamycin (TM; an inhibitor of protein glycosylation) groups (2 mg/kg in the same volume of PBS,i.p.; Sigma) once (n= 12 per time point group). One or two days later, their peripheral blood samples were collected, euthanized and their liver tissues were dissected.

To test the role of AFP in the CCl4-induced liver injury, the mice were randomized and treated intravenously with 1×1010recombinant serotype 8 adeno-associated virus (rAAV8) for expression of control short hairpin RNA (shRNA) orAfp-specific shRNA (Table 2, Genechem, Beijing, China). Six weeks after infection, the levels of AFP expression in the livers of mice were analyzed by Western blot to confirmAfpsilencing. The mice with control shRNA orAfp-specific shRNA were administrated with olive oil or CCl4as the control shRNA + olive oil, CCl4(control shRNA + CCl4),AfpshRNA + olive oil, orAfpshRNA + CCl4(AfpshRNA + CCl4). Their peripheral blood samples were collected, euthanized and their livers were dissected at 36 h (n= 12 per group) post CCl4administration, based on our preliminary studies.

Cell lines and culture

Human hepatocyte LO2 and hepatoma HepG2 cell lines were obtained from the Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China) and identified by STR. The cells were cultured in RPMI-1640 containing 10% fetal bovine serum, 100 Units/mL of penicillin and 100 μg/mL of streptomycin at 37 °C in a 5% CO2incubator. To induce ER stress, LO2 cells were treated with, or without (NC group), solvent control group (dimethyl sulfoxide, DMSO) and 0.5 μmol/L thapsigargin(TG; an inhibitor of intracellular calcium balance) in DMSO (Sigma, TG group) for 12 h, 24 h and 48 h,respectively.

In addition, LO2 cells (1.2 × 106cell/well) were cultured in 6-well plates overnight and transfected with plasmids for control shRNA,PERK-specific shRNA andATF6-specific shRNA (Beijing Genechem)using lipofectamine 3000 (Fisher). Two days later, the cells were treated with vehicle DMSO or TG for 24h. Additionally, LO2 cells were transfected with plasmid for the expression of control shRNA orAFPspecific shRNA (Beijing Genechem) for 48 h and treated with DMSO or TG for 36 h, respectively.

Table 1 The demographic and clinical data of subjects

Western blot analysis

LO2, HepG2 cells, or individual liver samples were homogenized in immunoprecipitation assay lysis buffer (R0010, Solarbio, Beijing, China). After centrifugation, individual liver lysates (40 μg) were separated in sodium dodecyl sulfate polyacrylamide gel on 10% gels and transferred to polyvinylidene fluoride membranes (Millipore, Billerica, MA, United States). The membranes were blocked with 5%skim dry milk in TBST (Tris-HCl buffer salt solution + Tween 20) and probed with mouse monoclonal antibodies (mAb) against AFP (sc-130302; Santa Cruz Biotechnology, Santa Cruz, CA, United States),ATF6 (sc-166659, 1:1000, Santa Cruz Biotechnology), GAPDH (sc-166545, 1:10000, Santa Cruz Biotechnology), CHOP (GADD153, sc-71136, 1:10000, Santa Cruz Biotechnology), eIF2α (sc-133132, 1:10000,Santa Cruz Biotechnology), phosphorylated PERK (p-PERK, MA5-15033, 1:1000, Thermofisher Scientific,United States), and PERK (sc-377400, 1:10000, Santa Cruz Biotechnology), or rabbit monoclonal antibodies against cleaved caspase-3 (9664, 1:10000, Cell Signaling Technology), and phosphorylated eIF2α (p-eIF2α, 3398, 1:10000, Cell Signaling Technology), or rabbit polyclonal antibodies against phosphorylated MLKL (p-MLKL, PA5-105677, 1:2000, Thermofisher Scientific), and MLKL (PA5-34733,1:3000, Thermofisher Scientific). After reaction with horseradish peroxidase (HRP)-conjugated antimouse or anti-rabbit IgG, the immunocomplexes were visualized with enhanced chemiluminescent reagents. Quantity One software (Bio-Rad, Hercules, CA, United States) was used to determine the relative levels of each targeted protein to the control (standardized as 1)[18].

Pathological analysis of liver tissue

Fresh liver tissues (5 mm × 5 mm in size from each mouse or 1 mm × 30 mm in size from one patient)were fixed in 4% paraformaldehyde for ≥ 24 h, paraffin-embedded and cut. The liver tissue sections (5 μm) were dewaxed, rehydrated and routine-stained with hematoxylin and eosin (H&E). The sections were examined under a light microscope (OLYMPUS CX31) using CaseViewer 2.4 software(3DHISTECH, Hungary). The necrotic areas in the liver were analyzed by Image-Pro Plus 6.0 (Media Cybernetics, United States)[19]. The Histology Activity Index-Knodell scores were determined by two pathologists blindly[20].

Immunohistochemistry

The liver tissue sections were dewaxed, rehydrated and blocked with 3% of bovine serum albumin for 20 min. The sections were incubated with mAb against AFP (sc-130302, 1:250) at 4 °C overnight and the bound antibodies were detected with HRP-conjugated anti-mouse IgG, followed by visualizing with diaminobenzidine. The intensity of anti-AFP staining was evaluated by Image Pro Plus 6.0[19].

TUNEL assay

The effect ofAfpsilencing on the frequency of apoptotic hepatocytes in liver sections was determined by terminal deoxynucleotidyl transferase (TdT)-mediated deoxyribonucleotide derivative digoxigenin(dUTP) nick end labeling (TUNEL) using a specific kit (Roche, 11684817910), according to the manufacturer’s instruction. Briefly, the paraffin-embedded liver sections were dehydrated, permeabilized, and incubated with a mixture of TdT and dUTP at 1:14 in a humidified chamber for 2 h at 37 °C.The labeled cells were detected with detection solution and after being washed, the sections were counterstained with 4′, 6-diamidino-2-phenylindole. The TUNEL signals were examined under a fluorescent microscope. The apoptotic cells were defined by nuclear green staining while non-apoptotic cells with blue nuclear staining. Five visual fields in each section were randomly selected and the percentages of apoptotic cells in each section were calculated using the formula of positive cells/total cells × 100%.

Analysis of AFP levels

AFP levels in the supernatant of cultured cells and mouse serum samples were measured by chemiluminescence immunoassay on the Beckman Coulter Auto Analyzer (Model DX1800; 04481798190, Roche Diagnostics GmbH) as previously described[21]. Samples were centrifuged to remove the remaining cells and possible cell debris before testing the AFP concentration.

Alanine aminotransferase and total bilirubin levels

The levels of serum alanine aminotransferase (ALT), total bilirubin (TBil) were two commonly used measures of liver injury, and analyzed by an auto-analyzer (AU5800, Beckman Coulter, United States)[22].

Cell viability assay

The impact of specific gene silencing or ER stress on LO2 cell viability was determined using the cell counting kit-8 (CCK-8; Cat. No. 40203ES60; Yeasen Biotechnology, Shanghai, China), per the product instruction. Briefly, LO2 cells (5000 cells/100 μL medium/well in 96-well plates) were treated with, or without, TG for 48 h (5 replicates per sample). During the last one-hour culture, the cells were exposed to CCK-8 and the absorbance of individual wells was detected at a wavelength of 450 nm (Bio-Rad, CA,United States). The relative cell viability (%) = (OD value of the treatment group-OD value of the blank group)/(OD value of the control group-OD value of the blank group) × 100.

Statistical analysis

Data are representative images or expressed as the mean ± SD of each group from 3 separate experiments. The difference of normally distributed values among groups was analyzed by one-way ANOVA and post hoc Tukey’s method. The difference between groups was analyzed by Student’sttest. Survival rates were estimated using the Kaplan-Meier method and analyzed by the log-rank test. AP-value less than 0.05 was considered statistically significant.

RESULTS

AFP expression is induced in the liver of patients with chronic liver injury

To explore the potential role of AFP in the progression of chronic hepatocyte injury, we analyzed AFP expression in liver tissues of patients with CHB (n= 34), controls (liver trauma;n= 8), and those with HCC (positive controls,n= 8). While there were healthy hepatocytes without degeneration and necrosis in the control liver tissues there were many hepatocytes undergoing degeneration and necrosis(Figure 1A). Immunohistochemistry indicated positive anti-AFP staining in the liver tissues from patients with HCC or CHB, but little in the controls. Interestingly, the positively stained anti-AFP was particularly in the regions with hepatocyte degeneration and necrosis of the liver tissues from CHB patients. Further Western blot displayed significantly increased levels of AFP expression in the livers from HCC or CHB patients, relative to that in the controls (P ＜0.01, Figure 1B). Such data indicated that AFP expression was induced in hepatocytes, associated with hepatocyte degeneration and necrosis in humans during the process of hepatocyte injury.

Figure 1 The intrahepatic levels of alpha-fetoprotein protein are elevated in injured livers. A: Immunohistochemistry and hematoxylin and eosin(H&E) staining analyzed alpha-fetoprotein (AFP) expression and pathological changes, respectively, in liver tissues of patients with chronic hepatitis B (CHB, n = 34),trauma (n = 8) or hepatocellular carcinoma (HCC, the positive control group, n = 8). The upper panels display immunohistochemical staining, and the lower panels exhibit H&E staining in sequential tissue sections. The positive expression of AFP was stained with brownish yellow by immunohistochemistry and indicated by the arrows; B: The relative levels of AFP protein expression were analyzed by Western blot in the liver specimens indicated. H&E: Hematoxylin and eosin; IHC-P:Immunohistochemistry-paraffin; AFP: Alpha-fetoprotein; HCC: Hepatocellular carcinoma; CHB: Chronic hepatitis B. bP ＜ 0.01, compared with the control group.

Induction of liver injury enhances AFP expression and ER stress in the liver of mice following CCl4 administration

Figure 2 Administration with carbon tetrachloride induces alpha-fetoprotein expression, endoplasmic reticulum stress and liver injury in mice. Male BALB/c mice were untreated (NC), or administrated with olive oil (control) or carbon tetrachloride (CCl4) for 24 h, or 8 wk. A: Serum alanine aminotransferase levels; B: Serum total bilirubin levels; C: Hematoxylin and eosin staining analysis of pathological changes in mouse liver tissues at 24-h and 8-wk post CCl4; D: Chemiluminescence immunoassay of serum alpha-fetoprotein (AFP) levels; E: Western blot analysis of the relative levels of AFP expression in liver tissues of mice; F: Immunohistochemical staining of AFP expression in liver tissue of mice at 24-h post CCl4, the positive expression of AFP was stained with brownish yellow and indicated by a plus sign; G: Western blot analysis of the relative levels of protein kinase R-like endoplasmic reticulum kinase phosphorylation and activating transcription factor-6 expression in liver tissues of mice. AFP: Alpha-fetoprotein; ALT: Alanine aminotransferase; ATF6: Activating transcription factor-6;CCl4: Carbon tetrachloride; H&E: Hematoxylin and eosin; PERK: Protein kinase R-like endoplasmic reticulum kinase; TBil: Total bilirubin. bP ＜ 0.01 compared with the control group.

Next, we tested whether AFP expression could be induced in the liver of mouse model of CCl4-induced hepatocyte injury. As expected, CCl4administration significantly elevated serum ALT (P ＜0.05;Figure 2A), TBil (P ＜0.05; Figure 2B) levels, accompanied by increased areas of liver tissue necrosis in mice, relative to the NC and the control groups (olive oil) of mice (P ＜0.05; Figure 2C), particularly in the livers of mice following administration with CCl4for 8 wk. There were similarly low levels of serum AFP detected in the different groups of mice (about 0.61 ng/mL, Figure 2D). In contrast, Western blot revealed that CCl4administration obviously up-regulated AFP expression in the livers of mice in a trend of time-dependence (P ＜0.05; Figure 2E). Further immunohistochemistry exhibited that the upregulated AFP expression was mainly accumulated in the injured liver areas (Figure 2F). Finally, CCl4administration significantly enhanced the relative levels of PERK phosphorylation and ATF6 expression(P ＜0.05; Figure 2G), the hallmarks of enhancing ER stress in the livers of mice. Collectively, CCl4administration induced hepatocyte injury and ER stress, and up-regulated AFP expression, but not its secretion in mice.

ER stress up-regulates AFP expression in hepatocytes

Given that up-regulated AFP expression was associated with enhanced ER stress, we tested whether induction of ER stress could up-regulate AFP expression in TM-injected mice. Compared with the NC and vehicle controls, significantly elevated levels of serum ALT (P ＜0.05; Figure 3A) and TBil (P ＜0.05;Figure 3B) were detected in mice at 24 h and 48 h post TM injection, implicating that induction of ER stress induced liver damages in mice. Consistently, Western blot revealed that TM injection obviously up-regulated ATF6, and AFP expression and PERK phosphorylation in the livers of mice, relative to that of the controls (P ＜0.05; Figure 3C). Interestingly, there were damaged liver areas with strong anti-AFP staining in the mice with TM injection (Figure 3D). However, there were similar levels of serum AFP in the different groups of mice (＜ 0.61 ng/mL, Figure 3E). Furthermore, while there was no detectable AFP in the supernatants of cultured human non-tumor hepatocyte LO2 cells, even after treatment with TG,the levels of AFP in the supernatants of cultured HepG2 cells increased in a time-dependent manner(Figure 3F). Moreover, TG treatment significantly decreased the viability of LO2 cells at 24 h and 48 h post treatment (P ＜0.05, Figure 3G), but TG treatment significantly enhanced the relative levels of AFP and ATF6 expression and PERK phosphorylation in LO2 cells (P ＜0.05, Figure 3H). Thus, induction of ER stress induced hepatocyte injury and AFP expression.

ATF6 silencing mitigates the TG-induced AFP expression in LO2 cells

To understand how ER stress promoted AFP expression, we transfected LO2 cells withPERKorATF6-specific shRNA. We found thatPERKsilencing significantly reduced the viability of LO2 cells (P ＜0.05),and deteriorated the TG-induced damages in LO2 cells (P ＜0.01; Figure 4A). WhilePERKsilencing significantly reduced the levels of PERK protein expression in both regular cultures and TG-treated LO2 cells, and mitigated the relative levels of TG-enhanced eIF2α phosphorylation in LO2 cells,PERKsilencing failed to significantly alter AFP protein expression in LO2 cells regardless of TG treatment(Figure 4B). In contrast,ATF6silencing significantly reduced the viability of LO2 cells, but enhanced the TG-induced damages in LO2 cells (P ＜0.01; Figure 4C). Moreover, transfection withATF6shRNA not only significantly inhibited ATF6 expression, but also attenuated the relative levels of AFP expression in both regular cultures and TG-treated LO2 cells (P ＜0.01; Figure 4D). Hence,ATF6silencing mitigated the TG-induced AFP expression in LO2 cells.

Figure 3 Endoplasmic reticulum stress up-regulates alpha-fetoprotein expression in hepatocytes. Male BALB/c mice were untreated (NC), or treated with phosphate buffer saline (control) or TM for 24 h or 48 h. LO2 cells were untreated (NC), or treated with dimethyl sulfoxide (control) or thapsigargin (TG)for 24 h, and 48 h. A: Serum alanine aminotransferase levels; B: Serum total bilirubin levels; C: Western blot analysis of the relative levels of proteins; D:Immunohistochemical analysis of alpha-fetoprotein (AFP) expression and hematoxylin and eosin staining analysis of liver injury in mice at 24 h post endoplasmic reticulum stress. The positive expression of AFP was stained with brownish yellow and indicated by a plus sign. Hash sign indicates the area of necrosis; E:Chemiluminescence immunoassay of serum AFP levels in mice; F: The levels of AFP in the supernatants of cultured cells; G: Cell counting kit-8 analysis of the cell viability; H: Western blot analysis of the relative levels of p-protein kinase R-like endoplasmic reticulum kinase, ATF6 and AFP expression in LO2 cells. AFP: Alphafetoprotein; ALT: Alanine aminotransferase; ATF6: Activating transcription factor-6; CCl4: Carbon tetrachloride; CCK-8: Cell counting kit-8; DMSO: Dimethyl sulfoxide;H&E: Hematoxylin and eosin; IHC-P: Immunohistochemistry-paraffin; PBS: Phosphate buffer saline; p-PERK: Phosphorylated protein kinase R-like endoplasmic reticulum kinase; TBil: Total Bilirubin; TM: Tunicamycin; TG: Thapsigargin. bP ＜ 0.01, compared with the control group; dP ＜ 0.01, compared with the 0 h group in HepG2 cells.

Figure 4 Activating transcription factor-6 silencing inhibits the expression of alpha-fetoprotein induced by thapsigargin in vitro. LO2 cells were transfected with control shRNA, protein kinase R-like endoplasmic reticulum kinase (PERK)-shRNA, or activating transcription factor-6 (ATF6)-shRNA for 48 h,and treated with dimethyl sulfoxide (control) or thapsigargin for 24 h. A: Cell counting kit-8 (CCK-8) analysis of cell viability; B: Western blot analysis of p-PERK,phosphorylated eukaryotic translational initiation factor 2 alpha, and alpha-fetoprotein expression; C: CCK-8 analysis of cell viability; D: Western blot analysis of the relative levels of ATF6 and AFP protein expression. AFP: Alpha-fetoprotein; ATF6: Activating transcription factor-6; CCK-8: Cell counting kit-8; DMSO: Dimethyl sulfoxide; p-eIF2α: Phosphorylated eukaryotic translational initiation factor 2 alpha; p-PERK: Phosphorylated protein kinase R-like endoplasmic reticulum kinase; TG:Thapsigargin. aP ＜ 0.05, bP ＜ 0.01, compared with these two groups.

AFP silencing increases the TG-induced hepatocyte apoptosis and necroptosis in LO2 cells

To understand the importance of AFP in ER stress-induced hepatocyte injury, we further explored the impact ofAFPsilencing on the ER stress-induced hepatocyte injuryin vitro. Compared with the control LO2 cells, transfection withAFP-specific shRNA, but not the control shRNA, dramatically reduced AFP expression in LO2 cells (P ＜0.01; Figure 5A), and deteriorated the TG-induced damages (P ＜0.01), but it did not significantly alter the viability of LO2 cells (P＞ 0.05, Figure 5B). Furthermore, theAFPsilencing significantly increased the levels of cleaved caspase-3 and MLKL phosphorylation regardless of TG treatment (P ＜0.05, Figure 5C). Consistently,AFPsilencing also significantly increased CHOP expression and PERK phosphorylation, but decreased ATF6 expression in LO2 cells (P ＜0.01,Figure 5D). These results clearly indicated thatAFPsilencing enhanced spontaneous and TG-induced ER stress, apoptosis and necroptosis in LO2 cells.

AFP silencing deteriorates the CCl4-induced liver injury in mice

Finally, we tested whether induction ofAfpsilencing could modulate the CCl4-induced liver injury in mice. After intravenous administration with rAAV8 virus for the expression of control orAfp-specific shRNA for 6 wk, the levels of AFP expression in the liver tissues were reduced dramatically, confirming theAfpsilencing (P ＜0.01, Figure 6A). Both groups of mice were administrated with vehicle olive oil or CCl4and 36 h later, we found thatAfpsilencing increased serum ALT (P ＜0.01, Figure 6B), and TBil levels (P ＜0.01, Figure 6C), regardless of CCl4administration. Compared with the control mice,Afpsilencing increased the percentages of necrotic areas in the livers of mice (P ＜0.01, Figure 6D).Furthermore,Afpsilencing decreased AFP expression, but remarkably increased the relative levels of cleaved caspase-3 expression, MLKL phosphorylation (P ＜0.01, Figure 6E) and the percentages of apoptotic hepatocytes in the livers of both vehicle and CCl4-treated mice (P ＜0.01, Figure 6F). Finally,Afpsilencing significantly increased CHOP expression and PERK phosphorylation, but decreased ATF6 expression in the livers of CCl4-treated mice (P ＜0.01; Figure 6G). Therefore,Afpsilencing enhanced ER stress and liver injury induced by CCl4 in mice.

DlSCUSSlON

In this study, we investigated AFP expression, its regulatory mechanism, and its effect on hepatocyte injury during the process of liver injury. We detected high levels of AFP expression in the livers, particularly in the areas of hepatocyte necrosis, of patients with CHB, but not in those with hepatic trauma.Similarly, high levels of AFP expression were observed in the livers of mice following CCl4administration and ER stress induction. The induced AFP expression was accompanied by liver injury in those patients and mice. Interestingly, there was no significant difference in the levels of serum AFP in those experimental patients and mice, compared to the controls. Moreover, induction of ER stress in human non-tumor hepatocyte LO2 cells also induced AFP expression, hepatocyte apoptosis and necroptosis,but failed to detect AFP in the supernatants of cultured cells. These indicated that during chronic liver diseases, ER stress and other inducers triggered hepatocyte apoptosis and necroptosis and stimulated AFP expression, but limited its secretion, leading to increased levels of intracellular AFP in hepatocytes.These novel data extended our previous study on hepatoma cells[15], and support the notion that AFP can be induced during the process of chronic liver diseases[7,23]. Our findings may shed light on the liver responses to ER stress in the pathogenic process of chronic liver diseases.

Low levels of serum AFP are detected in patients with chronic liver disease, and are positively correlated with the degrees of liver damages[8,24]. Although high levels of AFP expression were detected in mouse livers, we did not detect abnormally high levels of serum AFP in liver-injured mice,consistent with our observation in hepatoma cells[15]. These indicated that ER stress induced intracellular AFP expression by limiting its secretion. Given that healthy hepatocytes do not express AFP in adults it is possible that ER stress-induced hepatocyte injury may also induce compensative hepatocyte proliferation to repair liver damages in these models. However, the induced intracellular AFP is unlikely from the proliferation and differentiation of liver precursor cells. We are interested in further investigating how ER stress limits the secretion of AFP in hepatocytes during the process of chronic liver diseases.

AFP expression is regulated in a manner of tissue-specific and time-restriction[25]. Previous studies have shown that AFP expression is regulated by transcription factors, such as hepatocyte nuclear factor-1 (HNF1), ACCAAT-enhancer binding protein (C/EBP) and NF-1 and their enhancers[26-28].Furthermore, the mutation in the AFP promoter region can increase the binding affinity of HNF1,leading to sustained increase in the levels of AFP expression[29]. Moreover, the AFP promoter activity is also regulated by the competitive modulation of these transcription factors, activators and inhibitors[30]. In this study, we explored how ER stress induced AFP expression in hepatocytes. ER stress mainly enhances eIF2α activation and regulates the expression of target molecules through ATF4, ATF6, and XBP1 to enhance cell ability to eliminate and degrade misfolded proteins[11]. We found thatATF6, but notPERK, silencing significantly mitigated the ER stress-induced AFP expression in LO2 cells. These data suggest that ATF6 may promote AFP expression in hepatocytes under an ER stress condition.

Figure 5 Silencing of alpha-fetoprotein exacerbates the thapsigargin-induced LO2 cell injury. A: Western blot determined alpha-fetoprotein silencing in LO2 cells; B: Cell counting kit-8 analysis of LO2 cell viability; C: Western blot for the relative levels of indicated protein expression in LO2 cells; D:Western blot for the relative levels of endoplasmic reticulum stress-related protein. AFP: Alpha-fetoprotein; CCK-8: Cell counting kit-8; ER: Endoplasmic reticulum;TG: Thapsigargin; p-MLKL: Phosphorylated mixed lineage kinase domain-like pseudokinase; p-PERK: Phosphorylated protein kinase R-like endoplasmic reticulum kinase. Data are typical images or expressed as the mean ± SD of each group from 3 separate experiments. bP ＜ 0.01 compared with these two groups.

Figure 6 Silencing of alpha-fetoprotein increases liver injury in mice following CCl4 administration. A: Western blot for the protein levels of alphafetoprotein (AFP) in the liver tissues of mice; B: Serum alanine aminotransferase levels; C: Serum levels of total bilirubin; D: Liver sections stained by hematoxylin and eosin and measurements of necrotic areas in mice; E: Western blot for the relative levels of AFP, cleaved caspase-3, and phosphorylated mixed lineage kinase domain-like pseudokinase expression in the liver tissues; F: TUNEL analysis of hepatocyte apoptosis; G: The relative levels of phosphorylated protein kinase R-like ER kinase, activating transcription factor-6 and C/enhancer binding protein homologous protein protein in liver tissues. AFP: Alpha-fetoprotein; ALT: Alanine aminotransferase; ATF6: Activating transcription factor-6; CCl4: Carbon tetrachloride; CHOP: C/enhancer binding protein homologous protein; H&E: Hematoxylin and eosin; p-MLKL: Phosphorylated mixed lineage kinase domain-like pseudokinase; p-PERK: Phosphorylated protein kinase R-like ER kinase; TBil: Total bilirubin;TUNEL: Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling. bP ＜ 0.01 compared with these two groups.

Functionally, AFP can act as a carrier to maintain plasma colloidal osmotic pressure and transport bilirubin, estrogen, fatty acids, retinoids, steroids and progesterone to regulate hormone homeostasis[31]. Second, AFP can induce immune cell apoptosis and down-regulates the gene expression of a variety of inflammatory factors, inhibiting autoimmunity and aberrant inflammation by protecting the fetus from maternal immune attack and attenuating the immune clearance of tumors[32,33].Furthermore, AFP can enhance the malignant behavior of hepatoma cells by inhibiting their apoptosis and autophagy[34,35]. Accordingly, AFP can promote the survival and growth of a variety of tumor and non-tumor cells[36,37]. AFP can reduce the tumor necrosis factor alpha (TNF-α)-mediated damages of liver cancer cells or hepatocytes, and promotes their proliferation[38,39]. Studies have found that AFP can enhance the expression of p53, c-fos, c-jun, N-ras and hepatocyte growth factor receptor by binding to its receptors to activate the cyclic adenosine 3’, 5’-monophosphate (cAMP)-protein kinase A (PKA)pathway and induce Ca2+influx. This process increases intracellular cAMP and PKA, and promotes the proliferation, differentiation and regeneration of hepatocytes. In this study,Afpsilencing deteriorated the ER stress-mediated apoptosis and necroptosis of LO2 cellsin vitro. Preferable liverAfpsilencing also aggravated the CCl4-induced liver damages, hepatocyte apoptosis, and necroptosis in mice. The results suggest that the induced AFP expression in the liver by ER stress may enhance the resistance of hepatocytes to apoptosis and necroptosis stimulators, alleviating liver injury. Interestingly, we found that AFP silencing also exacerbated the ER stress, but lowed ATF6 expression in LO2 cells and in hepatocytes of liver tissues in mice, consistent with our previous observation[15]. These findings suggest that intracellular AFP induced by the ATF6 signaling may feedback-attenuate the ER stressinduced hepatocyte apoptosis and necroptosis, partially by up-regulating ATF6 expression. Given that AFP is not a transcription factor for the ATF6 expression the ER stress-induced AFP expression may through signal-crosstalk induce the ATF6-specific transcription factor and activator expression,indirectly inducing ATF6 expression in hepatocytes in a condition of ER stress.

We have reported that ATF6 is important for hepatocyte apoptosis and programmed necrosis[40]. It is possible that intracellular AFP may interact with intracellular proteins, transcription factors, kinases, coactivators and cell cycle regulators, such as PTEN to activate the PI3K/AKT/mTOR signaling to support the hepatocyte survival[41]. In addition, intracellular AFP may also interact with the apoptosisrelated signaling to enhance apoptosis resistance by up-regulating Bcl-2 expression[35]. However, how intracellular AFP mitigates the ER stress-induced hepatocyte injury remains to be further examined.

CONCLUSlON

ER stress induced intracellular AFP expression through activating ATF6 and the induced intracellular AFP feedback-attenuated the ER stress-induced hepatocyte injury. Thus, our findings may shed lights on the molecular regulation by which hepatocytes respond to ER stress, promoting compensative liver repair following ER stress-induced liver injury.

ARTlCLE HlGHLlGHTS

FOOTNOTES

Author contributions:Chen YF, Liu SY, and Cheng QJ contributed equally to this work; Chen YF, Liu SY, Cheng QJ,and He YH conceived and designed research; Chen YF, Liu SY, Wang YJ, Chen S, Zhou YY, and Liu X collected data and conducted research; Jiang ZG, Chen YF, and Zhong WW analyzed and interpreted data; Chen YF, Liu SY, and Cheng QJ wrote the initial paper; He YH and Zhong WW revised the paper; He YH had primary responsibility for final content; all authors read and approved the final manuscript.

Supported bythe National Natural Science Foundation of China, No. 81560110; Tian Qing Liver Disease Research Fund Project of the Chinese Foundation for Hepatitis Prevention and Control, No. TQGB20200001; and the Science and Technology Planning Projects of Guizhou Province and Zunyi City, No. QKH·ZC[2019] 2803, No. QKHJCZK[2022]YB642, No. QKH·PTRC[2017]5733-013, No. gzwjkj2020-1-041, No. ZSKHSZ[2020]230, and No.ZMC·YZ[2018]38.

lnstitutional review board statement:The study was reviewed and approved by the Ethics Committee of Affiliated Hospital of Zunyi Medical University (ZYFYLS[2018] 28).

lnstitutional animal care and use committee statement:All procedures involving animals were reviewed and approved by the Animal Experiment Ethics Committee of Zunyi Medical University (LS[2020] 2-231).

Conflict-of-interest statement:There are no conflicts of interest to report.

Data sharing statement:The datasets generated and analyzed during the current study are available from the corresponding author on reasonable request.

ARRlVE guidelines statement:The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.

Open-Access:This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BYNC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is noncommercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Country/Territory of origin:China

ORClD number:Yun-Fen Chen 0000-0002-7940-7481; Si-Ying Liu 0000-0001-9938-4232; Qi-Jiao Cheng 0000-0002-3746-5923; Yu-Jiao Wang 0000-0002-9077-4979; Shuang Chen 0000-0001-9879-7529; Yi-Yang Zhou 0000-0002-1549-1821; Xia Liu 0000-0003-4140-184X; Zhi-Gang Jiang 0000-0003-4539-6988; Wei-Wei Zhong 0000-0002-9736-8148; Yi-Huai He 0000-0002-8639-3436.

S-Editor:Chen YL

L-Editor:A

P-Editor:Yuan YY